

GP 1614#5  
6/4/02  
82

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-193US

In Re Application Of: ANAND et al.


Serial No.  
09/998,115 ✓

Filing Date  
11/30/2001 ✓

Examiner

Group Art Unit  
167

Title: 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE  
ALPHA1-ADRENOCEPTOR BLOCKERS



Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
MAY 24 2002  
TECH CENTER 1600/2900

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-193US

In Re Application: ANAND et al.

Serial No.

09/998,115

Filing Date


11/30/2001

Examiner

Group Art Unit

1614

1,4-DI-~~DISUBSTITUTED~~ PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE



RECEIVED  
MAY 24 2002  
TECH CENTER 1600/2900

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on May 21, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Signature of Person Mailing Correspondence

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.



Signature

Dated: May 21, 2002

Jayadeep R. Deshmukh, Esq.

Reg. No. 34, 507

Ranbaxy Laboratories Limited

600 College Road East, Suite 2100

Princeton, New Jersey 08540

Telephone: (609) 720-5608

Facsimile: (609) 514-9779

CC: